Expansile Nanoparticles Encapsulate Factor Quinolinone Inhibitor 1 and Accumulate in Murine Liver upon Intravenous...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Drug Delivery Systems

Background:

• Expansile nanoparticles (eNPs) are pH-responsive polymeric vehicles for drug delivery.
• Previous studies were limited to intraperitoneal injection and paclitaxel delivery.
• Intravenous administration and broader therapeutic applications require further investigation.

Purpose of the Study:

• To evaluate the biodistribution and in vivo toxicity of eNPs after intravenous injection in mice.
• To assess the potential of eNPs as a delivery platform for hepatocellular carcinoma treatment.
• To investigate the pH-dependent release and efficacy of FQI1-loaded eNPs in liver cells.

Main Methods:

• Intravenous injection of eNPs in mice to assess biodistribution and toxicity.
• In vitro studies using human liver cells (cancerous and noncancerous) to evaluate eNP uptake.
• pH-dependent drug release assays and cell proliferation assays for FQI1-loaded eNPs.

Main Results:

• eNPs predominantly localized to the liver following intravenous administration.
• No detectable acute toxicity was observed in the liver or other key organs.
• FQI1-loaded eNPs demonstrated pH-dependent drug release and inhibited hepatocyte proliferation in vitro.

Conclusions:

• eNPs are a versatile platform delivery system with potential for treating liver diseases.
• Intravenous administration of eNPs is safe and leads to liver accumulation.
• eNPs show promise for targeted delivery of therapeutics like FQI1 for hepatocellular carcinoma.